Media coverage about Aquinox Pharmaceuticals (NASDAQ:AQXP) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aquinox Pharmaceuticals earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.3219070877777 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news headlines that may have effected Accern’s scoring:

A number of equities research analysts have recently issued reports on AQXP shares. BidaskClub upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $25.00 target price on shares of Aquinox Pharmaceuticals in a research note on Tuesday, May 8th. Zacks Investment Research upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, May 15th. ValuEngine upgraded Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Aquinox Pharmaceuticals in a research note on Wednesday, June 27th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $20.80.

Shares of AQXP stock traded down $0.06 during trading hours on Friday, reaching $3.11. The company had a trading volume of 198,988 shares, compared to its average volume of 751,060. Aquinox Pharmaceuticals has a twelve month low of $1.96 and a twelve month high of $16.90. The firm has a market cap of $74.61 million, a P/E ratio of -1.45 and a beta of -13.81.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings data on Wednesday, August 8th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.71. The business had revenue of $25.00 million for the quarter.

In other Aquinox Pharmaceuticals news, Director Daniel J. Levitt sold 3,906 shares of the firm’s stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $12.67, for a total transaction of $49,489.02. Following the completion of the sale, the director now owns 3,906 shares in the company, valued at approximately $49,489.02. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.70% of the stock is owned by company insiders.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers.

Recommended Story: NASDAQ Stock Market Explained

Insider Buying and Selling by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.